The Neuroscience of 8 Major Psychiatric Disorders — Maximum Detail

1. SCHIZOPHRENIA

Why It Happens — Core Neurodevelopmental Story

The Three Interconnected Pathway Hypothesis

1. Mesolimbic Pathway — Positive Symptoms (Dopamine HYPERACTIVITY)

• Origin: Ventral Tegmental Area (VTA) → Nucleus Accumbens (NAc), limbic system
• Receptor: D2 receptors (Gi-coupled, inhibitory) in the striatum/NAc
• What happens: Excessive D2 stimulation in the NAc → hyperactive limbic processing → delusions, hallucinations, thought disorder
• How glutamate drives it: Cortical pyramidal neurons normally activate GABAergic interneurons (specifically PV-positive fast-spiking interneurons) in the VTA, which suppress mesolimbic dopamine release. In schizophrenia, NMDA receptor hypofunction on these GABA interneurons (NMDA receptors require glycine/D-serine co-agonist and glutamate simultaneously to open) means the "brakes" on mesolimbic dopamine are gone → dopamine floods the NAc → positive symptoms.

2. Mesocortical Pathway — Negative & Cognitive Symptoms (Dopamine HYPOACTIVITY)

• Origin: VTA → DLPFC, anterior cingulate cortex (ACC)
• Key difference from mesolimbic: In the mesocortical circuit, the VTA dopamine neurons targeting the PFC lack the same GABA interneuron arrangement — so hyperactive cortical glutamate neurons here actually over-inhibit dopamine release to PFC.
• Result: Too little D1 stimulation in DLPFC → impaired working memory, flat affect, poverty of speech, anhedonia (negative symptoms) and cognitive deficits
• D1 receptors (Gs-coupled, excitatory) on DLPFC pyramidal cells are critical for PFC function via cAMP signaling. Insufficient D1 tone = DLPFC hypofunction ("hypofrontality" seen on PET/fMRI)

3. Nigrostriatal Pathway — Not Pathological in Untreated Schizophrenia

• Origin: Substantia Nigra pars compacta (SNc) → Dorsal Striatum (caudate/putamen)
• This pathway controls motor function. It is normal in untreated schizophrenia but is targeted — often excessively — by D2 antagonist antipsychotics, causing extrapyramidal side effects (EPS), tardive dyskinesia (TD).

NMDA Hypofunction — The Master Upstream Mechanism

1. Glutamate binding (GluN2 subunit)
2. Glycine/D-serine co-agonist (GluN1 subunit)
3. Relief of Mg²⁺ block (voltage-dependent)

• Less GABA inhibition → cortical pyramidal neurons disinhibited → excessive glutamate output
• This glutamate over-drives mesolimbic dopamine → positive symptoms
• AND over-inhibits mesocortical dopamine via a separate VTA GABA interneuron → negative symptoms

Serotonin — The Third Arm

• Reduces hallucinations directly
• Increases mesocortical dopamine release (by blocking the serotonin-mediated inhibition of VTA mesocortical neurons) → partially rescues negative/cognitive symptoms
• Reduces nigrostriatal D2 blockade side effects

2. MAJOR DEPRESSIVE DISORDER (MDD)

Why It Happens — Converging Hypotheses

Level 1: The Monoamine Hypothesis (Classic — Necessary but Insufficient)

• Reserpine (depletes monoamines) → depression
• Monoamine oxidase inhibitors (MAOIs) → antidepressant
• Tricyclic antidepressants (block 5-HT/NE reuptake) → antidepressant

• 5-HT1A (autoreceptor, Gi-coupled, inhibitory): Presynaptic 5-HT1A autoreceptors in raphe nuclei fire when serotonin is high → reduce 5-HT synthesis and release. Postsynaptic 5-HT1A in hippocampus/cortex → anxiolytic, mood-stabilizing
• 5-HT2A/2C (Gq-coupled, excitatory): Hyperactivation associated with depressive and anxious symptoms
• 5-HT3 (ionotropic, Na+/K+): Mainly GI and emesis; not a primary mood receptor
• Alpha-2 adrenergic autoreceptors (Gi-coupled): On NE neurons in the locus coeruleus; when stimulated → reduce NE release. SNRIs/TCAs eventually desensitize these autoreceptors, increasing NE tone — explaining the 2–3 week lag to therapeutic effect
• Beta-1 adrenergic receptors (Gs-coupled): Hippocampus; reduced numbers in depression

Level 2: The HPA Axis — Stress and Cortisol

• Cortisol acts via glucocorticoid receptors (GRs) and mineralocorticoid receptors (MRs) — both nuclear receptors (ligand-activated transcription factors)
• Hippocampal neurons are exceptionally dense in GRs — making them highly vulnerable to cortisol toxicity
• Chronic hypercortisolemia → hippocampal volume loss (documented on MRI in MDD): inhibits neurogenesis in the dentate gyrus, promotes dendritic atrophy of CA3 pyramidal neurons, increases glutamate excitotoxicity via NMDA overactivation
• Depression = HPA axis fails to downregulate (dexamethasone suppression test is abnormal in ~50% of severely depressed patients)

Level 3: Neurotrophin/Neurotrophic Hypothesis — BDNF

• TrkB activation → PI3K/Akt, MAP kinase/ERK, and PLCγ pathways → cell survival, dendritic growth, synaptogenesis
• Chronic stress reduces BDNF and TrkB expression in hippocampus and PFC
• All effective antidepressants (SSRIs, SNRIs, TCAs, MAOIs, ECT, ketamine) upregulate BDNF/TrkB in the hippocampus — with a time course of 10–20 days that mirrors therapeutic onset
• CREB (cAMP response element-binding protein) is a downstream transcription factor activated by increased cAMP from monoamine GPCRs — it drives BDNF gene expression
• The BDNF Val66Met polymorphism (substitution in the prodomain) impairs activity-dependent BDNF secretion, increases anxiety, impairs fear extinction, and confers genetic vulnerability to depression and anxiety disorders

Level 4: Glutamate — Ketamine and the Rapid-Acting Revolution

• Depression involves decreased AMPA/NMDA ratio in the PFC and hippocampus
• Ketamine blocks tonic NMDARs on GABA interneurons → disinhibition of glutamate pyramidal neurons → burst of glutamate → AMPA receptor activation → TrkB transactivation → BDNF release → rapid synaptogenesis
• RAPA (mTOR pathway) activation by ketamine is essential for its synaptogenic effect
• Downstream: synaptic AMPA receptor insertion and spine growth in VLPFC/mPFC within hours — this is the structural substrate of rapid antidepressant action

Level 5: Neuroinflammation

• Activate IDO (indoleamine 2,3-dioxygenase) → diverts tryptophan away from serotonin synthesis → toward kynurenine pathway → neurotoxic quinolinic acid (NMDA agonist) accumulates → excitotoxicity
• Directly impair monoamine reuptake transporters (SERT, NET)
• Activate microglia → release more glutamate and cytokines (positive feedback loop)

Circuits in MDD

• sgACC (subgenual anterior cingulate cortex) / Area 25: Hyperactive in depression; deep brain stimulation of this area produces rapid antidepressant effects
• vmPFC: Impaired emotion regulation; fails to suppress amygdala activity
• Amygdala: Hyperreactive to negative emotional stimuli — explains rumination and negative bias
• Dorsal striatum and reward circuits: Hypoactive → anhedonia
• Hippocampus: Atrophy (volume loss) correlates with duration/severity of untreated depression

3. BIPOLAR DISORDER

Why It Happens

Neurobiological Core

• Valproate → blocks voltage-gated Na⁺ channels AND increases GABA synthesis (by inhibiting GABA transaminase) AND inhibits protein kinase C (PKC)
• Lamotrigine → blocks voltage-gated Na⁺ and Ca²⁺ channels → reduces glutamate release from presynaptic terminals (especially relevant in depressive phase)

• Dopamine release in the striatum
• CREB activation and BDNF expression
• Regulation of the circadian clock (CLOCK genes) Disruption of Cav1.2 → aberrant calcium influx → destabilized circadian signaling and dopamine dysregulation

Dopamine in Mania vs. Depression

• Mania: Excess dopamine in mesolimbic circuits → euphoria, grandiosity, decreased need for sleep, psychomotor acceleration. D2/D3 receptor hypersensitivity and/or excessive dopamine release. Antipsychotics (D2 blockers) are effective acutely.
• Depression phase: Same circuits as MDD — reduced mesolimbic dopamine and serotonin, HPA hyperactivation, BDNF reduction

Lithium — The Prototypical Mood Stabilizer: Molecular Mechanisms

1. Inositol monophosphatase (IMPase) inhibition: Lithium blocks the recycling of inositol → depletes inositol → reduces IP3/DAG second messenger signaling downstream of Gq-coupled receptors (including mGluR1, 5-HT2, muscarinic M1) — the "inositol depletion hypothesis"
2. GSK-3β inhibition: Lithium directly inhibits glycogen synthase kinase-3β (GSK-3β), a serine/threonine kinase with vast downstream effects including:
   • Regulation of circadian clocks (phosphorylates CLOCK/BMAL1)
   • Wnt/β-catenin signaling (neurotrophic, neuroprotective)
   • Tau phosphorylation (relevant to neuroprotection)
3. PKC inhibition (also shared with valproate): Reduces excessive intracellular signaling cascades during mania
4. BDNF/TrkB/Bcl-2 upregulation: Lithium increases BDNF, upregulates Bcl-2 (anti-apoptotic), and promotes neurogenesis — explaining why long-term lithium treatment preserves hippocampal gray matter volume

Circadian Dysregulation

• Alter melatonin release from the pineal gland (melatonin acts on MT1/MT2 receptors — Gi-coupled)
• Impair the sleep-wake regulation machinery of the suprachiasmatic nucleus (SCN)
• Trigger manic or depressive episodes (sleep deprivation is a potent mania trigger; agomelatine targets MT1/MT2 + 5-HT2C for its antidepressant/mood-stabilizing effect)

4. ANXIETY DISORDERS (GAD / Social Anxiety / Generalized)

The Amygdala-Centered Fear Circuit

• Sensory input (lateral nucleus receives from thalamus and cortex)
• Contextual memory (hippocampal input: "when and where is this dangerous?")
• Emotional regulation (vmPFC and OFC input: "is this still threatening?")

Receptors and Neurotransmitters

• Pentameric ligand-gated Cl⁻ channels (most abundant = α1β2γ2)
• GABA binding opens the channel → Cl⁻ influx → hyperpolarization → neuronal silencing
• Benzodiazepines (BZDs) bind the allosteric BZ site (between α and γ subunits) — positive allosteric modulators (PAMs): they do NOT open the channel alone, but increase the frequency of channel opening when GABA is present
• α1 subunit: sedation, anterograde amnesia
• α2/α3 subunits: anxiolysis, muscle relaxation
• BZDs hypothetically blunt amygdala output AND suppress CSTC (cortico-striato-thalamo-cortical) worry loops by enhancing GABAergic interneurons in those circuits

• SSRIs are first-line for most anxiety disorders. Mechanism: chronic 5-HT elevation → desensitization of 5-HT2C receptors (which are anxiogenic) → net anxiolysis
• 5-HT1A receptors in amygdala and raphe are anxiolytic (buspirone = partial agonist at 5-HT1A)

• Locus coeruleus (LC) → projects broadly to amygdala, prefrontal cortex, hippocampus via NE
• In anxiety, LC is hyperreactive → excessive NE release → α1 adrenergic receptor activation in amygdala → heightened arousal and fear
• Beta-blockers (propranolol) block peripheral β-adrenergic receptors → reduce heart palpitations, sweating, tremor (performance anxiety somatic symptoms). Propranolol also has CNS effects
• Alpha-2 agonists (clonidine, guanfacine) suppress LC firing → reduce NE tone → anxiolytic

• Presynaptic N and P/Q type VSCCs control glutamate/NE release in amygdala and CSTC circuits
• Pregabalin and gabapentin (α2δ ligands) bind the α2δ subunit of these VSCCs → reduce excitatory neurotransmitter release → anxiolytic and anti-worry effects

• Corticotropin-releasing hormone (CRH) acts at CRH-R1 receptors in the amygdala, locus coeruleus, and hippocampus → directly drives anxiety and HPA activation. CRH-R1 antagonists are in clinical trials for anxiety/depression.

The CSTC Worry Loop

• Prefrontal cortex → striatum → thalamus → back to cortex
• In GAD: stuck in a hyperactive worry loop, perpetuating repetitive, uncontrollable thoughts
• Glutamate drives this circuit; BZDs and α2δ ligands suppress it
• SSRIs/SNRIs gradually recalibrate the loop

5. PANIC DISORDER

What Makes Panic Different from Other Anxiety

The Locus Coeruleus / Norepinephrine System

• Located in the pons; ~50,000 neurons bilaterally with widespread projections to entire brain
• LC hyperactivation → massive NE release → panic-like physiological storm

• α1 adrenergic (Gq-coupled, excitatory): In cortex and amygdala → arousal, fear, cardiac activation
• α2 adrenergic (Gi-coupled, inhibitory autoreceptor): On LC neurons — when stimulated → reduce firing. Yohimbine (α2 antagonist) provokes panic attacks experimentally by removing this brake
• β-adrenergic receptors (Gs-coupled): In heart/peripheral vasculature — palpitations; in brain — contributes to emotional memory consolidation (why traumatic memories are vivid and intrusive)

• Amygdala ↔ parabrachial nucleus in the brainstem (regulates breathing)
• In panic: amygdala activation stimulates the parabrachial nucleus → sensation of suffocation, dyspnea → escalating fear (positive feedback loop)
• CO2 hypersensitivity: Panic patients are hypersensitive to CO2 inhalation — activates pH-sensitive ion channels (ASICs, acid-sensing ion channels) in the amygdala directly

6. POST-TRAUMATIC STRESS DISORDER (PTSD)

Why It Happens — Fear Conditioning Gone Pathological

The Core Circuit Malfunction

1. Lateral amygdala is hyperactivated; synaptic strengthening is exaggerated
2. vmPFC (ventromedial PFC) — normally suppresses amygdala output via GABAergic projections — is hypoactive in PTSD. It cannot extinguish the conditioned fear.
3. Hippocampus: Normally provides contextual disambiguation ("I'm safe now, not in the combat zone"). In PTSD, chronic stress-induced hippocampal atrophy and reduced neurogenesis impair contextual discrimination → generalized fear triggers (any car backfire = threat)

HPA Axis — Paradoxically Low Cortisol

• Enhanced negative feedback (GRs are upregulated/supersensitive)
• Paradoxically, low cortisol fails to terminate the stress response properly
• High CRH levels in CSF (CRH drives LC → NE storm → hyperarousal and flashbacks)

Fear Extinction — Why It Fails in PTSD

• vmPFC BDNF/TrkB signaling is impaired
• NMDA receptor-dependent LTP at vmPFC-amygdala synapses is insufficient
• BDNF Val66Met carriers have significantly impaired extinction learning — explaining genetic vulnerability to PTSD
• D-cycloserine (partial NMDA co-agonist at the glycine site) enhances fear extinction in experimental and early clinical settings

Pharmacology Targets

• SSRIs/SNRIs: Increase 5-HT tone → reduce amygdala hyperreactivity (first-line)
• Prazosin: α1 adrenergic blockade → reduces nightmare severity (NE drives consolidation of traumatic memories during REM)
• MDMA-assisted therapy: MDMA floods 5-HT, dopamine, and NE → blunts amygdala fear response while enhancing therapist bond (oxytocin release) → allows traumatic memory processing without overwhelming fear reconditioning

7. EATING DISORDERS (Anorexia Nervosa, Bulimia Nervosa)

Hypothalamic Hunger/Satiety Axis

• NPY/AgRP neurons in the arcuate nucleus (ARC) of the medial hypothalamus
• NPY acts at Y1/Y5 receptors (Gi) → stimulates feeding
• AgRP is an inverse agonist at MC4R (melanocortin 4 receptor) → blocks satiety signaling
• Activated by ghrelin (stomach-derived, acts at GHSR1a — Gs-coupled) — the "hunger hormone"

• POMC/CART neurons also in ARC
• POMC is cleaved to α-MSH → acts at MC4R (Gs-coupled) in the paraventricular nucleus (PVN) → reduces food intake, increases metabolism
• Activated by leptin (adipocyte-derived, acts at LepRb — JAK2/STAT3 signaling) — signals adiposity/energy stores
• BDNF/TrkB signaling in the PVN is essential for satiety: loss-of-function mutations in TrkB cause severe hyperphagia and obesity in humans and mice

Serotonin in Eating Disorders

• Bulimia Nervosa: Responds to SSRIs (fluoxetine is FDA-approved) — increasing 5-HT tone at 5-HT2C receptors reduces binge-purge cycles
• Low 5-HT synthesis and turnover documented in recovered anorexia and bulimia patients (tryptophan depletion worsens symptoms)

Dopamine — Reward and Anhedonia

• Anorexia: Dopamine dysregulation in the dorsal striatum → aberrant reward processing of food stimuli; food becomes aversive rather than rewarding
• D2 receptor hypersensitivity in the dorsal striatum of anorexia patients (PET imaging with [11C]raclopride) → heightened sensitivity to small dopamine signals → extreme restriction behavior may itself become rewarding (dopaminergic reinforcement of restriction)
• Bulimia: Binge eating → massive dopamine surge in NAc → followed by crash → guilt/purging

Insula and Interoception

• Anterior insula is abnormally active or insensitive to hunger cues
• fMRI studies show altered insula activation in response to food images in both anorexia (excessive activation → disgust) and bulimia

Genetics and Serotonin Transporter

8. BORDERLINE PERSONALITY DISORDER (BPD)

Why It Happens — Emotional Dysregulation and Neurodevelopment

Core Circuit: Amygdala Hyperreactivity + Prefrontal Hypofunction

• Amygdala: Hyperactivated by interpersonal emotional stimuli (faces showing rejection, abandonment cues). The amygdala in BPD fires faster and stronger — and takes longer to return to baseline (prolonged emotional reactivity)
• vmPFC and DLPFC: Hypoactive — cannot perform the "top-down" inhibition of the amygdala that normal emotional regulation requires
• Anterior cingulate cortex (ACC): Also hypoactive — impaired cognitive control over emotional responses
• Insula: Hyperactive — exaggerated interoceptive sensitivity (may contribute to chronic feelings of emptiness and dysphoria)

Serotonin — The Impulsivity Axis

• Reduced CSF 5-HIAA (5-hydroxyindoleacetic acid, the main serotonin metabolite) is found in impulsive/aggressive individuals and correlates with self-harm behavior
• 5-HT2A receptor density changes in the PFC → impaired cognitive regulation
• SSRIs modestly improve affective instability and impulsivity in BPD (though not as dramatically as in depression)

Opioid System — Abandonment Pain

• Dysregulated µ-opioid receptor signaling → extreme pain on perceived abandonment (social rejection activates the same dorsal ACC circuits as physical pain)
• Naltrexone (µ-opioid antagonist) reduces dissociative symptoms and self-harm urges in some BPD patients — consistent with a role for endogenous opioids in dissociation as self-analgesia

Norepinephrine and Dissociation

• NE hyperreactivity (via α1 receptors) in limbic regions → hyperarousal, emotional storms
• Extreme stress in BPD can trigger dissociative states — possibly via endogenous opioids or NMDA receptor-mediated mechanisms

HPA Axis in BPD

• Early childhood trauma → epigenetic changes in the GR (NR3C1) gene promoter (methylation) → altered HPA sensitivity, mimicking the PTSD pattern
• CRH hypersecretion in amygdala drives emotional hyperreactivity

CROSS-CUTTING NEUROSCIENCE THEMES

Key Receptors Master Reference

1. Schizophrenia — The three dopamine pathway model (mesolimbic D2 hyperactivity → positive symptoms; mesocortical D1 hypoactivity → negative symptoms; nigrostriatal → side effects). Upstream driver: NMDA receptor hypofunction on PV+ GABAergic interneurons disinhibiting glutamate, which drives the dopamine imbalance. Plus the 5-HT2A serotonin arm and why second-gen antipsychotics block both D2 and 5-HT2A.
2. Depression — Five converging levels: monoamine hypothesis (5-HT1A, α2 autoreceptors), HPA axis (cortisol/GR-mediated hippocampal atrophy), neurotrophic hypothesis (BDNF→TrkB→CREB cascade), glutamate/ketamine rapid synaptogenesis via AMPA/mTOR, and neuroinflammation (IDO → kynurenine → quinolinic acid as an NMDA agonist).
3. Bipolar — Kindling/anticonvulsant model; CACNA1C (L-type Ca²⁺ channel) as the top genetic hit; lithium's molecular targets (IMPase inhibition, GSK-3β inhibition, PKC, BDNF upregulation); circadian clock gene disruption.
4. Anxiety — Amygdala-centered circuit + CSTC worry loop; GABA-A receptor PAM mechanism of benzodiazepines (α1 = sedation, α2/α3 = anxiolysis); α2δ VSCCs for pregabalin; CRH-R1 in amygdala; NE locus coeruleus hyperreactivity.
5. Panic — LC NE storm (α1/α2/β receptors); parabrachial nucleus/suffocation alarm; CO2 hypersensitivity via amygdala ASICs; CCK-B receptors; why SSRIs take weeks to work (5-HT1A autoreceptor desensitization).
6. PTSD — Fear conditioning (NMDA/AMPA LTP in lateral amygdala); vmPFC extinction failure; hippocampal atrophy and context failure; paradoxically low cortisol with hypersensitive GR; high CRH and NE; why prazosin, propranolol, and MDMA-assisted therapy work at the receptor level.
7. Eating Disorders — Hypothalamic ARC: NPY/AgRP (hunger) vs POMC/α-MSH (satiety) acting at MC4R; ghrelin (GHSR1a) and leptin (JAK/STAT); 5-HT2C for SSRIs in bulimia; mesolimbic D2 hypersensitivity and aberrant reward in anorexia; insula interoception.
8. BPD — Amygdala hyperreactivity + PFC hypofunction; serotonin impulsivity axis (5-HIAA ↓); µ-opioid system and social pain (naltrexone rationale); HPA epigenetic changes (GR methylation from childhood trauma); NE storms and dissociation.